Growth Metrics

Lineage Cell Therapeutics (LCTX) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to 0.25.

  • Lineage Cell Therapeutics' Equity Ratio fell 6334.53% to 0.25 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.25, marking a year-over-year decrease of 6334.53%. This contributed to the annual value of 0.69 for FY2024, which is 1027.55% up from last year.
  • Lineage Cell Therapeutics' Equity Ratio amounted to 0.25 in Q3 2025, which was down 6334.53% from 0.53 recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Equity Ratio ranged from a high of 0.93 in Q2 2021 and a low of 0.25 during Q3 2025
  • For the 5-year period, Lineage Cell Therapeutics' Equity Ratio averaged around 0.65, with its median value being 0.63 (2023).
  • Per our database at Business Quant, Lineage Cell Therapeutics' Equity Ratio skyrocketed by 1224.56% in 2022 and then crashed by 6334.53% in 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Equity Ratio (Quarter) stood at 0.53 in 2021, then rose by 12.25% to 0.59 in 2022, then increased by 5.86% to 0.63 in 2023, then grew by 10.28% to 0.69 in 2024, then tumbled by 64.48% to 0.25 in 2025.
  • Its last three reported values are 0.25 in Q3 2025, 0.53 for Q2 2025, and 0.71 during Q1 2025.